0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Opioid Inhibition of Luteinizing Hormone Secretion Compared in Developing Male and Female Sheep

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The sheep exhibits a marked sex difference in the timing of the pubertal increase in luteinizing hormone (LH). Male lambs undergo a reduction in sensitivity to inhibitory steroid feedback, leading to an increase in LH by 10 weeks of age, but females remain hypersensitive until 30 weeks of age. Endogenous opioids suppress LH secretion in the female lamb prepubertally and in adult male and female sheep. It has been suggested that a reduction in opioid inhibition of LH secretion is the signal to time puberty. Therefore, if a decrease in opioid tone occurs during sexual maturation, it should begin earlier in the male lamb than in the female. The objective of this study was to compare opioid inhibition of LH secretion in male and female lambs in relation to the timing of puberty. Our approach was to examine the response to the opioid antagonist naloxone at various ages in both sexes. To determine the timing of the pubertal LH rise in the presence of constant inhibitory steroid feedback, male and female lambs (n = 5 each) were gonadectomized at 3 weeks of age and implanted with a Silastic capsule of estradiol. They were then challenged with naloxone at 5, 11, and 23 weeks of age; blood samples were collected every 12 min for 8 hours, and lambs received naloxone (1 mg/kg i.v.) at hours 4, 5, 6, and 7. Mean LH before and during naloxone treatment was compared at each age. During the 4-hour pretreatment period, no LH pulses were evident in prepubertal females at 5, 11, or 23 weeks of age, and mean LH remained low (0.8 ± 0.05 ng/ml). In prepubertal males, mean LH was 1.5 ± 0.2 ng/ml at 5 weeks of age and rose at puberty to 6.8 ± 0.3 ng/ml by 23 weeks of age. Despite this sex difference in the timing of the pubertal LH rise, neither male nor female lambs increased LH secretion in response to naloxone until 23 wseeks of age. At this time, mean LH in females increased by 3.2 ± 0.7 ng/ml over pretreatment values in response to naloxone and increased by 5.0 ± 0.9 ng/ml in males. Thus, although opioid tone is expressed prepubertally in the female lamb, it is not evident until after puberty in the male. In a second experiment, we determined if increasing the concentration of estradiol in circulation affects the gonadotropin response to naloxone. LH pulse frequency during naloxone treatment did not differ in ovariectomized prepubertal females bearing 3-, 10-, or 30-mm implants of estradiol, although the larger implants of estradiol suppressed LH during the pretreatment period. These data suggest that increasing steroid negative feedback does not increase opioid tone, thereby reducing the gonadotropin response to a single dose of naloxone. Together, these studies provide evidence that in sheep the timing of the pubertal rise in LH secretion is not causally related to changes in opioid inhibition; rather, other factors including age or season may influence when endogenous opioids begin to serve a major role in modulating gonadotropin secretion in this species.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1992
          1992
          07 April 2008
          : 56
          : 6
          : 822-830
          Affiliations
          Reproductive Sciences Program and Departments of aPhysiology, bObstetrics and Gynecology, and cBiology, University of Michigan, Ann Arbor, Mich., USA
          Article
          126312 Neuroendocrinology 1992;56:822–830
          10.1159/000126312
          1369590
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Categories
          Original Paper

          Comments

          Comment on this article